Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. (Nasdaq: DYAI), doing business as Dyadic Applied BioSolutions, regularly issues news on its activities as a global biotechnology company producing precision-engineered, animal-free proteins and enzymes. This news page aggregates press releases and market updates that describe how Dyadic is advancing its microbial C1 and Dapibus™ expression platforms across life sciences, food and nutrition, and bio-industrial markets.
Readers can find announcements about commercial agreements and partnerships, such as collaborations with Proliant Health and Biologicals, Inzymes ApS, Fermbox Bio, BRIG BIO, and Opes Diagnostics. These items often cover milestones in recombinant serum albumin, transferrin, growth factors, non-animal dairy proteins, and industrial enzyme products like EN3ZYME™, as well as details on licensing structures, milestone payments, and revenue-sharing arrangements.
Dyadic’s news flow also includes financial results and corporate developments, including quarterly earnings releases, equity offerings, and updates on its strategic shift from a research-driven organization to a commercially focused biotechnology company. These releases highlight progress in expanding product pipelines, scaling manufacturing, and strengthening liquidity to support commercial growth.
Another recurring theme in DYAI news is technology and platform validation. Articles describe grant-funded programs with organizations such as the Bill & Melinda Gates Foundation and CEPI, peer-reviewed publications demonstrating the capabilities of the C1 platform for vaccine antigens, and the CRISPR/Cas9 license agreement with ERS Genomics that broadens Dyadic’s genetic engineering toolkit.
Investors, analysts, and industry participants can use this page to follow Dyadic’s evolving portfolio of recombinant proteins, its regional expansion efforts, and its responses to Nasdaq listing matters disclosed in SEC filings. Bookmark this section to review the company’s historical and ongoing news as it reports commercial milestones, scientific progress, and capital markets activity.
Dyadic International (NASDAQ:DYAI) announced its participation in key upcoming events, including the Jefferies Virtual Healthcare Conference on June 1, 2021, where CEO Mark Emalfarb will discuss advancements in its C1-cell protein production platform. This platform focuses on reducing costs for vaccines and drugs, particularly the COVID-19 vaccine candidate, DYAI-100, preparing for Phase 1 trials. Additionally, Dyadic will present at the BIO International Convention from June 10-18. A live webcast will be available on their website for both events.
Dyadic International (DYAI) is advancing its COVID-19 vaccine candidate, DYAI-100, towards a Phase 1 clinical trial aimed at proving safety and efficacy. The company aims to produce larger quantities of affordable COVID-19 vaccines using its proprietary C1 technology. Recent financial results indicate a revenue increase to $461,000 for Q1 2021, with R&D expenses rising to $1.8 million due to clinical trial costs. As of March 31, 2021, cash and equivalents were $27.4 million. Collaborations with Medytox and others are ongoing to develop variant vaccines.
Dyadic International, Inc. (NASDAQ: DYAI) announced its participation in several key biotechnology events aimed at advancing its innovative C1-cell protein production platform. A notable KOL Fireside Chat is scheduled for May 4, 2021, focusing on the potential of Dyadic's technology to address global health challenges. Key Opinion Leaders will include experts from renowned institutions. Additionally, Dyadic will present at the World Vaccine Congress and PEGS Boston, discussing advancements in vaccine development and manufacturing. Dyadic's C1 technology promises lower costs and enhanced production capabilities for biologic vaccines and drugs.
Dyadic International, Inc. (NASDAQ:DYAI) will report its financial results for the first quarter of 2021 on May 13, 2021. The company is known for its proprietary C1-cell protein production platform, which aims to reduce costs and improve the efficiency of biologic vaccines and drugs. A corporate update conference call is scheduled for 5:00 p.m. Eastern Time on the same day. The call will be accessible via a toll-free number or webcast, with an archive available on Dyadic's website shortly after the event.
Dyadic International (NASDAQ: DYAI) is hosting a fireside chat on May 4, 2021, at 10:00 AM ET to discuss its proprietary C1 protein production platform. This event will feature key opinion leaders from renowned institutions, discussing the platform's benefits, regulatory advantages, and case studies including successful antigen production for viruses. Dyadic aims to leverage the C1 platform to develop cost-effective, scalable solutions for vaccines and therapeutics, addressing global health challenges and emerging SARS-CoV-2 variants. Registration is available online.
Dyadic announced advancement of its COVID-19 vaccine candidate, DYAI-100, towards Phase 1 clinical trials, validating safety in humans. They've expanded partnerships in Korea and Southeast Asia with Medytox for next-gen variant vaccines. Cash reserves stand at $29.2 million as of December 31, 2020. The PR highlights increased R&D expenses to $3.87 million and a net loss of approximately $9.3 million for 2020. Despite a revenue decline to $1.6 million, the company is pursuing multiple collaborations and projects in infectious disease vaccines.
Dyadic International is advancing its proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial. The company has partnered with CR2O to validate the safety of C1 produced proteins and support further development. This step aims to create next-generation variant vaccines. Additionally, Dyadic has expanded its partnership with Medytox in Korea and Southeast Asia for next-gen COVID-19 vaccines. DYAI-100 has shown promising interim results with substantial immunogenicity in animal studies, prompting the engineering of new C1 cell lines for broader efficacy against emerging variants.
Dyadic International (NASDAQ: DYAI) announced an expansion of its partnership with Medytox to co-develop C1-manufactured COVID-19 vaccines. This collaboration aims to create vaccines that target multiple COVID-19 variants, including potential tetravalent and quadrivalent options. The project will provide local supply within the Republic of Korea and several Southeast Asian countries. Successful manufacturing protocols for the C1 technology have been transferred to Medytox, enhancing the capabilities for producing effective vaccines.
Dyadic International (NASDAQ: DYAI) has announced an expansion of its collaboration with Medytox, aimed at co-developing C1-enabled COVID-19 vaccines and boosters. This partnership, which began in July 2020, will target immunization against multiple COVID-19 variants. Dyadic has successfully transferred manufacturing protocols to Medytox, and if successful, the project will grant exclusive licensing rights for the Republic of Korea and Southeast Asia. The C1 platform is recognized for its potential in producing affordable, high-volume biologic products.
Dyadic announced progress in its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100. Successful challenge studies in human ACE2 transgenic mice indicated high neutralizing antibody levels, supporting potential efficacy. The vaccine is set for a Phase 1 clinical trial, anticipated to start in 2H 2021, managed by CR2O. This collaboration aims to develop scalable and affordable vaccines against COVID-19 variants. Dyadic is also engineering additional cell lines for variant-specific antigens, enhancing its market position.